Infectious Disease Treatment Market Research Report Information By Disease Type (Viral Diseases, Bacterial Diseases, Fungal Diseases, Parasitic Diseases and others), Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic and others), End User (Hospitals & Clinics, Ambulatory Care Centers and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

Infectious Disease Treatment Market Scenario

The Infectious Disease Treatment Market is expected to reach USD 77.84 Billion by 2030 at 8.10% CAGR during the forecast period 2022-2030.

Infectious diseases are caused due to organisms such as bacteria, viruses, fungi, or parasites. These diseases can be transmitted through insects, animals or by consuming contaminated food or water or by being exposed to the environment that is infected by these organisms.

Factors such as the rising prevalence of infectious diseases and increasing awareness regarding these diseases are expected to drive the market growth. According to an article published by the World Health Organization (WHO), nearly 50,000 people die suffering from infectious diseases every day.

However, stringent government regulations and low awareness regarding the treatment options in underdeveloped countries are expected to hamper the infectious disease treatment market growth.

Segmentation

The Infectious disease treatment market has been segmented into disease type, treatment, end-user, and region.

Based on disease type, the market has been divided into viral diseases, bacterial diseases, fungal diseases, parasitic diseases, and others.

The infectious disease treatment market, by treatment, has been segmented into antibiotics, antivirals, antifungals, anti-parasitic, and others.

The market, by end-user, has been segmented into hospitals & clinics, ambulatory care centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The infectious disease treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 

The infectious disease treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa market has been segmented into the Middle East and Africa.

Key Players

Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Janssen Global Services, LLC (US), Sanofi (France), GlaxoSmithKline PLC (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Aurobindo Pharma (India), Dr. Reddy's Laboratories (India), Cipla Inc. (India), Alkem Labs (India), AbbVie Inc. (US) are some of the key players operating in the infectious disease treatment market.

Regional Market Summary

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the infectious disease treatment market owing to the increasing patient population suffering from various types of infectious disease and the growing number of initiatives taken by the government to manage the spread of infectious diseases in the region. According to the Centers for Disease Control and Prevention, there were 54,285 new cases of Salmonella infection in 2017 in the US.

Europe is expected to hold the second-largest position in the infectious disease treatment market owing to the growing awareness and rising patient population suffering from various infectious diseases. According to the WHO, as of 2018, 14 million people in Europe are suffering from hepatitis C.

Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from bacterial infectious diseases and the rising number of initiatives taken by governments as well as private institutes to create awareness regarding infectious diseases. According to an article published by the National Center for Biotechnology Information (NCBI) in May 2018, nearly 22% of deaths of children below the age of 5 years in India are caused due to meningitis and pneumonia.

The infectious disease treatment market in the Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from various types of infectious diseases.

Market Of Infectious Disease Treatment, by Disease Type

• Viral Diseases


• Bacterial Diseases


• Fungal Diseases


• Parasitic Diseases


• Others

Market Of Infectious Disease Treatment by Treatment

• Antibiotics


• Antivirals


• Antifungals


• Anti-Parasitic


• Others

Market Of Infectious Disease Treatment by End User

• Hospitals and Clinics


• Ambulatory Care Centers


• Others

Market Of Infectious Disease Treatment by Region

• Americas




• North America




• US


• Canada




• Latin America

• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe

• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Intended Audience

• Biotechnology and Pharmaceutical Companies


• Research Institutes


• Hospitals and Clinics


• Ambulatory Surgical Centers


• Academic Institutes


• Government Organizations

Report Scope:

Report Attribute/Metric	Details
Market Size	USD 77.84 Billion
CAGR	8.10%
Base Year	2021
Forecast Period	2022-2030
Historical Data	2020
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Disease Type, Treatment, End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Janssen Global Services, LLC (US), Sanofi (France), GlaxoSmithKline PLC (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Aurobindo Pharma (India), Dr. Reddy's Laboratories (India), Cipla Inc. (India), Alkem Labs (India), AbbVie Inc. (US)
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	Factors such as the rising prevalence of infectious diseases. increasing awareness regarding these diseases are expected to drive the market growth

Frequently Asked Questions (FAQ) :